Niagen Bioscience Inc (NAGE) Common Stock USD0.001

Sell:$5.20Buy:$5.39Price increased$0.07 (1.36%)

Prices delayed by at least 15 minutes
Sell:$5.20
Buy:$5.39
Change:Price increased$0.07 (1.36%)
Prices delayed by at least 15 minutes
Sell:$5.20
Buy:$5.39
Change:Price increased$0.07 (1.36%)
Prices delayed by at least 15 minutes

Company Information

About this company

Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.

Key people

Robert N. Fried
Chief Executive Officer, Director
Ozan Pamir
Chief Financial Officer
Carlos Luis Lopez
Senior Vice President, General Counsel
Frank L. Jaksch
Chairman of the Board
Steven D. Rubin
Lead Independent Director
Ann Cohen
Independent Director
Gary Ng
Independent Director
Kristin Patrick
Independent Director
Click to see more

Key facts

  • Shares in issue
    79.81m
  • EPIC
    NAGE
  • ISIN
    US1710774076
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $441.73m
  • Employees
    104
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.